| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T347 |
0-40 |
Sentence |
denotes |
3.1.2 Substrate‐derived Mpro inhibitors |
| T348 |
41-131 |
Sentence |
denotes |
To date, no approved drugs or vaccines are available for treating a coronavirus infection. |
| T349 |
132-317 |
Sentence |
denotes |
In a race to identify chemotherapeutic options, various approaches, such as chemical synthesis, testing of natural products, and virtual screening of compound libraries, have been used. |
| T350 |
318-414 |
Sentence |
denotes |
The systematic design of inhibitors of CoV Mpro was essentially based on the enzyme's substrate. |
| T351 |
415-608 |
Sentence |
denotes |
In general, a substrate can be transformed into a good inhibitor by modifying part of its sequence such that it binds to the catalytic cysteine in either a reversible or an irreversible manner. |
| T352 |
609-746 |
Sentence |
denotes |
Peptide inhibitors are designed by attaching a reactive group (also known as warhead group) to peptides that mimic the natural substrate. |
| T353 |
747-892 |
Sentence |
denotes |
The partial peptide substrate sequence for SARS‐CoV‐1 Mpro is mentioned in Figure 10, indicating the specific subsite of each amino acid residue. |
| T354 |
893-950 |
Sentence |
denotes |
Figure 10 A, SARS‐CoV‐1 Mpro partial substrate sequence. |
| T355 |
951-1003 |
Sentence |
denotes |
B, (Overlay) structures of SARS‐CoV Mpro inhibitors. |
| T356 |
1004-1135 |
Sentence |
denotes |
Mpro, main protease; SARS‐CoV, severe acute respiratory syndrome coronavirus [Color figure can be viewed at wileyonlinelibrary.com] |
